Achilles therapeutics reports first quarter 2024 financial results and recent business highlights

– provided interim phase i/iia update on clonal neoantigen reactive t cells in advanced nsclc and melanoma – – evaluating the benefit of enhanced host conditioning with further data expected in 2h 2024 – – strong cash position of $112.3 million supports operations through 2025 – london, may 08, 2024 (globe newswire) -- achilles therapeutics plc (nasdaq: achl), a clinical-stage biopharmaceutical company developing ai-powered precision t cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the first quarter ended march 31, 2024, and recent business highlights. “just after the close of the first quarter, we shared the interim phase i/iia data from our ongoing chiron and thetis til-based cnet clinical trials which have given us important mechanistic learnings about the factors driving durable engraftment and immune evasion at an antigen level.
ACHL Ratings Summary
ACHL Quant Ranking